glp-1/gip/glucagon receptor agonist LY3437943, a novel triple glucagon, GIP, and GLP-1 for glycemic control and weight loss: From discovery to clinical proof of concept: Cell Metabolism Possible mechanisms of action of
Description
Participants consumed excess sodium, saturated fat, and calories
+0.55 kg)
Pyke, C
Integrating exercise, adequate protein intake, and potentially adjunctive pharmacotherapies is essential to mitigate this risk
ADM prescribing in September 2025 increased slightly compared to June 2025 (+5.2%)
doi: 10.1056/NEJMoa2107519 72 LudvikBGiorginoFJdarEFriasJPFernndez LandLBrownKet al
